Kiniksa Q3 ARCALYST revenue $112.2M (+73% YoY); FY guidance raised to $410-420M

Kiniksa Pharmaceuticals International, plc

2024-Q3 EPS reported -$0.48 revenue$300,703,000

ARCALYST Q3 net product revenue $112.2M, up 73% YoY; FY 2024 guidance raised to $410-420M from $405-415M.
Net loss narrowed to $12.7M from $13.9M; cash $223.8M, no debt.
Over 2,550 prescribers since launch; average therapy duration ~27 months.
Phase 2b trial of abiprubart in Sjögren's Disease enrolling/dosing; expects annual cash flow positivity.
Launched Life DisRPted campaign with Henrik Lundqvist and Carly Pearce.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.